1. 1504TiPNintedanib plus docetaxel in routine clinical practice: VARGADO, a German prospective non-interventional study (NIS) reflecting routine treatment conditions in an evolving NSCLC treatment landscape. (23rd October 2018) Authors: Grohe, C; Zander, I; Lüdtke-Heckenkamp, K; Blau, W; Krüger, S; Franke, C; Mueller-Huesmann, H; Brückl, W M; Basara, N; Ukena, D; Lang, S; Atz, J; Kaiser, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 55PEfficacy and safety of nintedanib and docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First interim results of the ongoing non-interventional study VARGADO (NCT02392455). (17th December 2018) Authors: Grohe, C; Gleiber, W; Haas, S; Mueller-Huesmann, H; Schulze, M; Atz, J; Kaiser, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 66P Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455). (15th December 2019) Authors: Grohe, C; Gleiber, W; Krüger, S; Mueller-Huesmann, H; Schulze, M; Atz, J; Kaiser, R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗